Aptevo Therapeutics Inc (APVO) EPS Estimated At $-0.71

June 20, 2017 - By Nellie Frank

 Aptevo Therapeutics Inc (APVO) EPS Estimated At $ 0.71

Investors wait Aptevo Therapeutics Inc (NASDAQ:APVO) to report on June, 30. its quarterly earnings Aptevo Therapeutics Inc’s Wall Street analysts see -7,200.00 % negative EPS growth, taking into account the $0.01 EPS reproted in the previous quarter, The stock increased 5.39% or $0.11 during the last trading session, reaching $2.15. About shares traded. Aptevo Therapeutics Inc (NASDAQ:APVO) has 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Aptevo Therapeutics Inc. is a biotechnology company. The company has market cap of $44.28 million. The Firm is focused on oncology and hematology therapeutics. It currently has negative earnings. The Firm is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics.

More notable recent Aptevo Therapeutics Inc (NASDAQ:APVO) news were published by: Seekingalpha.com which released: “Aptevo Therapeutics: A Biotech Spinoff With Potential” on September 22, 2016, also Globenewswire.com with their article: “Aptevo Therapeutics Augments Leadership Team” published on September 15, 2016, Quotes.Wsj.com published: “Aptevo Therapeutics Inc. APVO (US: Nasdaq)” on August 01, 2016. More interesting news about Aptevo Therapeutics Inc (NASDAQ:APVO) were released by: Seekingalpha.com and their article: “Aptevo: An Orphaned Spinoff” published on October 05, 2016 as well as Schaeffersresearch.com‘s news article titled: “Analyst Update: Aptevo Therapeutics Inc, PBF Energy Inc, and Cyberark Software Ltd” with publication date: September 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.